Covaxin was developed with seed strains received from the National Institute of Virology and the Phase-3 clinical trials have been co-funded by the ICMR.
The Drug Controller General of India (DCGI) on Tuesday accepted the 77.8% efficacy of Bharat Biotech’s Covaxin in the Phase-3 trials, reports fe Bureau in Pune. BB had submitted the data to the DCGI over the weekend and the Subject Expert Committee (SEC) reviewed the data at a meeting held on Tuesday.
With the SEC making its recommendation, the final approval from DCGI is awaited. However, BB has not confirmed the developments. BB is slated to hold its pre-submission meeting with the WHO on Wednesday, as part of the process to get an approval for the emergency use listing of the vaccine.
The vaccine maker has demonstrated clinical efficacy of 78-100% against severe Covid-19 disease, in the interim results, from the Phase-3 trials. The Phase-3 study enrolled 25,800 participants between 18-98 years, including 10% over the age of 60, with the analysis conducted 14 days after the second dose.
Covaxin was developed with seed strains received from the National Institute of Virology and the Phase-3 clinical trials have been co-funded by the Indian Council of Medical Research (ICMR).
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Life Style News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
